BAIYONG SHEN
2 clinical trials · Sponsor
| Record | Firm | Date |
|---|---|---|
| ctDNA-based Minimal Residual Disease Detection for Resected Pancreatic Adenocarcinoma (NCT05479708) | BAIYONG SHEN | 2023-08-09 |
| Molecular Subtyping for Prognosis Evaluation in Resected Pancreatic Adenocarcinoma (NCT05483257) | BAIYONG SHEN | 2018-03-14 |
Track BAIYONG SHEN automatically
Every clearance here is in the API, with alerts when new ones post.